ABSTRACT
INTRODUCTION
Diabetes is a chronic disorder affecting 285 million adults worldwide, a figure that is predicted to rise to an estimated 439 million over the next 20 years [1] . In the UK alone, 2.6 million people are affected, of whom approximately 90% have type 2 diabetes mellitus (T2DM).
T2DM is characterized by beta-cell dysfunction and a varying degree of insulin resistance. Obesity per se is the major contributory factor in development of insulin resistance and impaired glucose tolerance. Both obesity and poor glycemic control in T2DM, either in combination or independent of each other, increase the risk of cardiovascular disease and mortality [2] .
An integral part of the management strategy in T2DM is lifestyle modification. Medical therapy with oral glucose-lowering agents is then instituted in a stepwise approach, followed by initiation and then intensification of insulin therapy [3, 4] . Because the efficacy of most existing glucose-lowering agents reduces over time and beta-cell function continues to decline, glycemic targets are often not achieved. Moreover, the use of these agents is often limited by undesirable side effects, such as weight gain, hypoglycemia, fluid retention, and gastrointestinal (GI) intolerance. This subsequently leads to poor adherence to medication on the part of the patient, or reluctance to optimize medication on the part of the clinician, and hence to many patients not achieving glycemic targets in routine clinical practice.
The development of novel agents, such as incretin-based therapies, that provide improved glycemic control without weight gain and with a low risk of hypoglycemia are a welcome addition to the clinician's armamentarium.
A literature search was carried out using Medline and PubMed from March 1, 2011 to December 22, 2011 . This review provides an overview of the role of exenatide, one of the incretin-based agents, in the management of T2DM and its effect on associated cardiovascular risk factors as seen in both clinical trials and real-life observational studies.
INCRETIN-BASED THERAPIES
Incretins are gut hormones produced by the small intestine in response to oral ingestion of glucose, which accounts for more than 50% of insulin secretion after food intake.
These hormones include glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The higher insulin response to orally administered glucose than to parenterally administered glucose is known as the incretin effect, which is deemed to be impaired in T2DM [5] . Physiologically, GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4) and, hence, its action is short-lived. Thus, targeting GLP-1, either to increase its availability or to prolong its action, has become an attractive option in developing new therapeutic agents in the management of T2DM.
Currently, two classes of incretin-based therapy are available, the incretin enhancers and the incretin mimetics. GLP-1 promotes the glucoregulatory effect by increasing insulin secretion and suppressing glucagon. It also delays gastric emptying and acts centrally on the satiety center to reduce the food intake, thus facilitating weight loss [5] . Some studies have shown it to increase beta-cell proliferation and reduce apoptosis [5] . This may have an influence in delaying the disease progression.
There is emerging evidence suggesting that GLP-1 has a direct influence on myocardium and vascular endothelium, which could potentially improve cardiovascular outcomes, either via GLP-1R or independently of GLP-1R.
The exact mechanism underlying the cardioprotective effect has not been fully elucidated. Some studies suggest an increased myocardial sensitivity to insulin and myocardial glucose uptake independently of plasma insulin level [6] . Other studies indicate an inhibition of cardiac myocyte apoptosis via inflammatory mediators and activation of antioxidant genes to reduce fibrosis and left ventricular remodeling, thus restoring left ventricular function after myocardial infarction [7] . A review describes improvement in left ventricular function and myocardial oxygen consumption with GLP-1 infusion in chronic heart failure, myocardial infarction, coronary angioplasty, and coronary artery bypass graft, although study patient populations were small in number [8] . GLP-1 produces a vasodilatory effect through nitric oxide (NO) production in the endothelium, a mechanism independent of GLP-1R, in an isolated mouse heart model [9] .
However, this vasodilatory effect is also observed regardless of the NO pathway, indicating a direct action of GLP-1 on vascular smooth muscle through the GLP-1R [10] .
Furthermore, administration of exenatide was found to be associated with a reduction of inflammatory mediators, such as the highsensitivity C-reactive protein [11] . In the open-label follow-up, a subset of patients (n = 217) achieved 3.5 years of ExBID exposure and maintained a significant HbA 1c reduction of 1% (P \ 0.0001) and weight loss of -5.3 kg (P \ 0.0001) [18] .
GLP-1 ANALOGS
When ExBID was added to a TZD, the combination was also found to be effective.
TZDs are insulin sensitizers, which improve insulin action in muscle and adipose tissue with some reduction in hepatic glucose production. These complementary mechanisms rationalize the potential use of combining the two in management of T2DM. In a double-blind, placebo-controlled trial, patients with T2DM who were suboptimally controlled with TZD (with or without metformin) were investigated over a period of 16 weeks [19] . Addition of ExBID resulted in a placebo-subtracted reduction in HbA 1c of 0.98% and a significant weight loss of -1.51 kg (P \ 0.001). However, this study was of relatively short duration. Liutkuz et al. [20] reported a similar improvement in glycemic control in a study over a 26-week Barnett and colleagues conducted a crossover study where 138 patients were randomized to receive either ExBID followed by insulin glargine or vice versa over successive 16-week periods.
Glycemic control improved in both groups by 1.36%; however, patients lost weight while on ExBID and gained weight on insulin glargine, with a difference of -2.2 kg [25] . In all three studies, ExBID reduced prandial glucose excursions more than glargine, while glargine reduced fasting glucose concentrations more than ExBID [23] [24] [25] . When compared to treatment with biphasic insulin aspart, both treatments showed similar improvements in HbA 1c of approximately 1%, but showed a weight difference of -5.4 kg in favor of ExBID [26] .
Thus, the evidence to date has demonstrated that treatment with ExBID was noninferior to that of basal insulin or biphasic insulin in optimizing the glycemic control. In contrast to the weight gain observed with insulin, ExBID therapy has an added benefit of weight loss.
Efficacy as an Add-on Therapy to Insulin At present, the combined use of insulin and a GLP-1 analog is not licensed. In a nationwide audit in the UK, of the 4,857 patients treated with ExBID, nearly 40% (1,921) were on combination with insulin [28] . However, there is limited randomized data on the combined use of these therapies.
Buse and colleagues studied the efficacy of adding ExBID to basal insulin glargine in a randomized, placebo-controlled trial. Patients with T2DM whose glycemic control was not adequate on insulin glargine alone or in combination with metformin or pioglitazone were randomized into groups receiving either ExBID (n = 138) or placebo (n = 123). Addition of ExBID significantly reduced HbA 1c (-1.74 vs. -0.93%, P \ 0.001) without increased hypoglycemia. Mean body weight also decreased by -1.8 kg with exenatide and increased by ?1 kg with placebo [27] .
In a retrospective, real-life clinical study of 188 patients with T2DM who were receiving a combination of insulin and ExBID over 27 months, the greatest reduction in HbA 1c
was observed in the first 6 months (-0.66%) and the reduction was maintained at -0.54% over the next 18 months [29] . Mean body weight also progressively declined to -6.2 kg up to 18 months. A 1-year follow-up of 124 subjects from another observational study showed a significant -0.87% (P \ 0.001) reduction in HbA 1c and -5.2 kg (P \ 0.001) reduction in body weight when the combination was used [30] .
By study design, in the randomized, controlled trial, basal insulin requirement [27] . However, in the real-life study, the mean total daily dose of insulin was decreased in all patients up to 12 months (-14.8 U/day).
The changes thereafter were not statistically significant. The mean prandial insulin dose also decreased from baseline, ranging from -29.7 to -55.7% over 27 months, but with no significant change in basal insulin dose [29] . A greater and significant reduction in total daily dose of 45 U/day (P \ 0.001) was reported in the nationwide UK audit [28] .
In conclusion, the addition of exenatide to an insulin-based therapy in obese patients with inadequately controlled T2DM is associated with a reduction in mean HbA 1c and body weight in both randomized and real-life studies. [31] . However, the liraglutide dose used (1.8 mg) is higher than the dose recommended by the NICE (1.2 mg), and to date there is no head-to-head study comparing ExBID with liraglutide 1.2 mg. with ExER illustrates the effect of continuous exposure to exenatide over 24 h compared to short exposure with ExBID. In conclusion, both studies demonstrate the difference in glycemic efficacy of long-acting compared to short-acting exenatide, and treatment with ExER proved to be superior to that with ExBID.
Efficacy of ExER

Efficacy of ExER Compared to a DPP-4
Inhibitor, TZD, and Metformin The DURATION 2 study investigated the safety and efficacy of ExER against the maximum approved dose of a DPP-4 inhibitor or TZD in patients treated with metformin. In this double-blind, superiority trial, patients were randomized into either an ExER (2 mg), a sitagliptin (100 mg), or a pioglitazone (45 mg) arm. Treatment with ExER reduced HbA 1c (-1.5%) more significantly than sitagliptin (-0.9%) or pioglitazone (-1.2%). The reduction in fasting glucose was significantly greater with ExER (-1.8 mmol/L) than with sitagliptin (-0.9 mmol/L), but not with pioglitazone (-1.5 mmol/L). Similarly, a greater reduction in body weight was observed with ExER, a treatment difference of -1.5 kg with sitagliptin (P = 0.0002) and -5.1 kg with pioglitazone (P \ 0.0001) [34] . Thus, the addition of ExER to metformin achieved better glycemic control and weight loss than sitagliptin or pioglitazone.
The DURATION 4 study reported the efficacy of ExER as a monotherapy compared to the maximum tolerated dose of sitagliptin, pioglitazone, or metformin monotherapy in drug-naïve T2DM patients [36] . The reduction ExER was superior to that with insulin glargine. 
Efficacy of ExER Compared to Liraglutide
Metabolic Effect of Exenatide on Cardiovascular Parameters
It is well established that T2DM is a significant risk factor for cardiovascular disease (CVD), and improvement in glycemic control reduces both microvascular and macrovascular complications. The United Kingdom Prospective Diabetes Study (UKPDS) showed a 16% risk reduction for myocardial infarction which remained significant in a 10-year post-study follow-up of patients with intensive glycemic control (P = 0.01) [40] . The finding of increased higher mortality in the intensive glycemic control group of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was controversial, although nonfatal myocardial infarction occurred less in this group [41] . However, the Action in Diabetes and Vascular Disease (ADVANCE) trial showed a small but significant reduction in the incidence of both microvascular and macrovascular complications with intensive glucose lowering (hazard ratio [HR] = 0.09, P = 0.01) [42] . Furthermore, postprandial hyperglycemia is strongly associated with CVD and has been regarded by some as a more important CVD risk factor than fasting hyperglycemia [43] .
In patients with diabetes, intentional weight loss is associated with a 28% reduction in CVD and diabetes-related mortality [44] . Thus, weight loss rendered by treatment with either ExBID or ExER could potentially offer the beneficial effect of reducing CVD events and related mortality independent of other mechanisms mentioned previously. In a large, retrospective analysis performed on the Lifelink database, patients treated with ExBID, despite higher rates of coronary artery disease, obesity, hypertension, and hyperlipidemia, were less likely to have a CVD event (HR = 0.81, P = 0.01) and had lower rates of CVD-related hospitalization (HR = 0.88, P = 0.02) than patients not treated with exenatide [45] .
Peskin and associates studied the long-term effects of ExER by employing a validated mathematical Archimedes Model on data derived from the 52-week clinical trial.
Treatment with simulated ExER resulted in an earlier benefit and two-to three-times greater relative reductions in major CVD events by improving glycemic control and weight (EQw model-1), and by improving blood pressure and lipids (EQw model-2) with relative risk reductions of 12 and 17%, respectively, over 20 years [46] .
The EXenatide Study of Cardiovascular Event
Lowering (EXSCEL) is currently recruiting and is expected to complete by 2016 [47] . It is designed to determine whether treatment with ExER is associated with improved cardiovascular outcomes compared to standard care with traditional diabetes medication.
Effects of Exenatide on Blood Pressure
The mechanism for lowering blood pressure by exenatide appears to be related to weight loss. However, in salt-sensitive rodent models, GLP-1 treatment has been shown to have antihypertensive, cardioprotective, and renoprotective actions through natriuretic and diuretic effects [48] . As discussed previously, the action on endothelium and vascular smooth muscle, producing vasodilatory effects, may contribute to lowering of the blood pressure [9, 10] .
In the follow-up, open-label extension of the three AMIGO studies, addition of ExBID resulted in an improvement of both systolic blood pressure (SBP) and diastolic blood pressure (DBP), by -3.5 and -3.3 mmHg, respectively [18] . In a pooled analysis of six trials involving 2,171 subjects, treatment with ExBID over 6 months showed greater reductions in SBP, mainly in patients with high baseline SBP, compared to placebo (-2.8 mmHg, P = 0.0002) or insulin (-3.7 mmHg, P \ 0.0001), with no effect on DBP [49] .
In the HEELA study, there was a significant decrease in SBP with ExBID treatment, which was statistically and significantly different from the change with insulin glargine (-3.6 mmHg, P = 0.034) [23] . Both SBP (-2.7 mmHg) and DBP (-1.7 mmHg) decreased significantly from baseline and heart rate increased by 2.3 beats/ min when ExBID was added to basal insulin glargine [27] . The difference was also significant when compared to the placebo. Both ExBID and liraglutide reduce SBP and DBP; however, the increase in heart rate was significantly higher with liraglutide (3.28 vs. 0.69 beats/min, P = 0.0012) [31] .
Similarly, treatment with ExER resulted in a significant reduction in SBP from baseline, ranging from -2.9 to -4 mmHg in the DURATION 1, 2, 3, 5, and 6 studies, with little or no effect on DBP [33-35, 37, 38] . The improvement in SBP was significantly greater with ExER than with ExBID, sitagliptin, or insulin glargine, but not pioglitazone [33] [34] [35] 39] . Mean heart rate was found to be significantly increased from baseline (4 beats/ min, P \ 0.05) in patients treated with ExER, but not in those treated with glargine [35] . Thus, treatment with either ExBID or ExER consistently results in reduction of SBP.
Effects of Exenatide on Lipid Profile
The effects of treatment with exenatide on total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) have been widely reported in both randomized and observational studies.
When ExBID was added to metformin, a SU, or
Diabetes Ther (2012) 3:3 Page 11 of 16 the combination, no significant differences in lipid profile were observed in either the ExBID or the placebo group at the end of the initial 30-week period [14] [15] [16] . However, further extension of the study to 82 weeks demonstrated a significant increase in HDL-C (?0.12 mmol/L) and a reduction in triglyceride (-0.43 mmol/L) from the baseline [17] . The greatest improvement in lipid profile was found in patients with the greatest weight reduction. When patients were followed for up to 3.5 years, a significant improvement was found in all lipid parameters: 5% reduction in total cholesterol, 6% in LDL-C, and 12% in triglyceride, while the HDL-C increased by 24% [18] . Both total cholesterol and triglyceride concentrations decreased over 26 weeks with both ExBID and glargine, but only LDL-C decreased with ExBID in the HEELA study [23] .
In the DURATION studies, treatment with ExER has been shown to improve the lipid profile. Both total cholesterol and LDL-C were significantly reduced with ExER compared to ExBID, while fasting TG was reduced for both treatment modalities [33] . In the DURATION 2 study, HDL-C was significantly improved with ExER, sitagliptin, and pioglitazone, but a reduction in triglyceride was observed only with pioglitazone [34] . The reported findings to date on lipid parameters are variable, and thus further large-scale studies are needed before definite conclusions can be drawn.
SAFETY AND TOLERABILITY
Gastrointestinal Intolerance
ExBID is generally well tolerated and the most frequent adverse events were mild-to-moderate GI intolerance, mainly nausea (20-59%) and vomiting (10-15%), and were found to be dose dependent and to subside over the first few weeks of initiation [14] [15] [16] [17] [18] [19] [20] [21] . Compared to placebo, the occurrence of GI intolerance was higher in the exenatide treatment arm when exenatide was added to metformin, a SU, or a combination of metformin with a SU or TZD. Similarly, GI intolerance was more common with exenatide therapy when exenatide was added to insulin glargine or compared to a combination of glargine and premixed insulin [22] [23] [24] [25] [26] .
The most common treatment-emergent adverse event reported with ExER treatment was nausea (24-30%), followed by diarrhea (9-13.5%), vomiting (4-16%), constipation (3-10.8%), and pruritus at the injection site (2-10.8%) [33] [34] [35] [36] [37] [38] [39] . Nausea was reported in significantly fewer patients treated with the once-weekly than the BID preparation [33, 37] . GI intolerance was more common with ExER than with sitagliptin, pioglitazone, or insulin glargine, but less common than with liraglutide [34, 35, 38] .
Hypoglycemia
In a meta-analysis, mild-to-moderate hypoglycemia was more commonly reported with exenatide than with placebo (16 vs.
7%, relative risk ratio 2.3; 95% CI 1.1-4.9), especially when coadministered with a SU [50] .
Eleven percent reported hypoglycemia with combination treatment of exenatide and a TZD [19] .
When exenatide was compared to basal insulin glargine or premixed insulin, there was no significant difference in the overall incidence of symptomatic hypoglycemia [22] [23] [24] [25] [26] . The incidence of nocturnal hypoglycemia was reported to be lower with exenatide treatment than with insulin [22] [23] [24] [25] . The overall hypoglycemia rate was decreased after a reduction of the SU dose in patients treated with the exenatide and insulin combination [25] .
Furthermore, addition of exenatide to basal insulin glargine did not increase the risk of hypoglycemia. The number of hypoglycemic events per participant per year did not differ significantly between the exenatide and the placebo group (1.4 vs. 1.2, P = 0.49) [27] . However, in real-life clinical practice, hypoglycemic events were significantly higher after initiation of exenatide treatment (5.6 vs.
3.3%, P \ 0.001) and in insulin-treated compared with non-insulin-treated patients (8.9 vs. 6.1%, P \ 0.001) [28] .
It was consistently reported that treatment with ExER did not cause major hypoglycemic episodes [33] [34] [35] [36] [37] [38] [39] . The incidence of minor hypoglycemia during both ExER and ExBID treatment was limited to patients using concomitant SU therapy. When ExER was compared to sitagliptin and pioglitazone, the frequency of minor hypoglycemic episodes was low and was similar [34] . Symptomatic hypoglycemia was more common with insulin glargine treatment than with ExER (31 vs. 13%) [35] .
CONCLUSION
Incretin-based therapies, particularly GLP-1 analogs, offer an alternative option to currently available therapeutic agents in the management of T2DM. Treatment with either ExER or ExBID results in improvement in glycemic control comparable to any other existing agents, without increased risk of major hypoglycemia, and is associated with significant weight loss. It is generally well tolerated, and GI intolerance usually subsides a few weeks after initiation. There is also a trend of improvement in blood pressure and lipid profile, both of which could potentially offer a reduction in cardiovascular events.
Thus, it is a justifiable adjuvant therapy for patients whose disease is not adequately controlled on OADs. Concomitant use with insulin is not licensed yet, although it has proven efficacy in both randomized and real-life clinical practice. To the best of the authors' knowledge, no safety data exist on the use of exenatide in children, pregnant women, or the elderly to inform its safety in such patients, and hence it is not recommended in these patients. However, further continued and robust evaluation, in both randomized and clinical studies, is needed to determine the safety and efficacy of using ExBID and ExER in the long term. 
